Progression-free survival as a surrogate endpoint in advanced breast cancer

International Journal of Technology Assessment in Health Care

Volumn 24, Issue 4, 2008, Pages 371-383

  Miksad, Rebecca A ^a,b   Zietemann, Vera ^c   Gothe, Raffaella ^c   Schwarzer, Ruth ^c   Conrads Frank, Annette ^c   Schnell Inderst, Petra ^c   Stollenwerk, Björn ^c   Siebert, Uwe ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY FOR HEALTH SCIENCES   (Austria)

Author keywords

Advanced breast cancer; Meta analytic validation; Overall survival; Progression free survival; Surrogate endpoint

Indexed keywords

CHEMOTHERAPY; COMPUTER OPERATING SYSTEMS; FORECASTING; PATIENT TREATMENT; REGRESSION ANALYSIS; SENSITIVITY ANALYSIS; SHELTERS (FROM ATTACK); STATISTICAL METHODS;

ADVANCED BREAST CANCER; META-ANALYTIC VALIDATION; OVERALL SURVIVAL; PROGRESSION-FREE SURVIVAL; SURROGATE ENDPOINT;

INFRARED SPECTROMETERS;

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; TAXANE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; FOOD AND DRUG ADMINISTRATION; HAZARD RATIO; HUMAN; KAPPA STATISTICS; SENSITIVITY ANALYSIS; VALIDATION PROCESS;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TAXOIDS;

EID: 53149130962     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462308080495     Document Type: Article

References (68)

1. A'Hern RP, Ebbs SR, Baum MB. Does chemotherapy improve survival in advanced breast cancer? A statistical overview. Br J Cancer. 1988;57:615-618.
2. Ackland SP, Anton A, Breitbach GP, et al. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: A randomized multinational study. J Clin Oncol. 2001;19:943-953.
3. Aisner J, Cirrincione C, Perloff M, et al. Combination chemotherapy for metastatic or recurrent carcinoma of the breast - A randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. J Clin Oncol.1995;13:1443-52.
4. Altman DG. Practical statistics for medical research. 1st ed. New York: Chapman and Hall; 1991.
5. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed. Malden, MA: Blackwell Science; 2001.
6. Baker SG, Kramer BS. A perfect correlate does not a surrogate make. BMC Med Res Methodol. 2003;3:16.
7. Baker SG. Surrogate endpoints: Wishful thinking or reality? J Natl Cancer Inst. 2006;98:502-503.
8. Bennett JM, Muss HB, Doroshow JH, et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol. 1988;6:1611-1620.
9. Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol. 2002;20:3114-3121.
10. Bishop JF, Dewar J, Toner GC, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol. 1999;17:2355-2364.
11. Boccardo F, Rubagotti A, Rosso R, Santi L. Chemotherapy with or without tamoxifen in postmenopausal patients with late breast cancer. A randomized study. J Steroid Biochem. 1985;23:1123-1127.
12. Burzykowski T, Molenberghs G, Buyse M. The validation of surrogate end points by using data from randomized clinical trials: A case-study in advanced colorectal cancer. J R Stat Soc Ser A Stat Soc. 2004;167:103-124.
13. Burzykowski T, Piccart MJ, Sledge G, et al. A quantitative study of tumor response and progression-free survival as surrogate endpoints for overall survival in first-line treatment of metastatic breast cancer. 28th Annual San Antonio Breast Cancer Symposium. San Antonio, Texas, United States, 2005. Abstract 6084.
14. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26:1987-1992.
15. Buyse M, Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics. 1998;54:1014-1029.
16. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999;17:2341-2354.
17. Conte PF, Pronzato P, Rubagotti A, et al. Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: Results of a randomized cooperative trial. J Clin Oncol. 1987;5:339-347.
18. Conte PF, Baldini E, Gardin G, et al. Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A randomized trial of the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol. 1996;7:487-490.
19. De Gruttola V, Fleming T, Lin DY, Coombs R. Perspective: Validating surrogate markers-are we being naive? J Infect Dis. 1997;175:237-246.
20. De Gruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop. Control Clin Trials. 2001;22:485-502.
21. Del Mastro L, Venturini M, Lionetto R, et al. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: Results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group. J Clin Oncol. 2001;19:2213-2221.
22. Di Leo A, Bleiberg H, Buyse M. Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: A critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol. 2003;21:2045-2047.
23. Efron B. Estimating the error rate of a prediction rule: Improvement on cross-validation. J Am Stat Assoc. 1983;78:316-331.
24. Ejlertsen B, Pfeiffer P, Pedersen D, et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer. 1993;29A:527-531.
25. European Medicines Agency. Appendix 1 to the guidelines on the evaluation of anticancer medicinal products in man: Methodological considerations for using Progression Free Survival (PFS) as primary endpoint in confirmatory trials for registration [Draft]. www.emea.europa.eu/pdfs/human/ ewp/26757506en.pdf. December 2006.
26. Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being misled? Ann Intern Med. 1996;125:605-613.
27. Fleming TR. Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood). 2005;24:67-78.
28. Gelber RD, Goldhirsch A. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol. 1986;4:1772-1779.
29. Gelber RD, Gelber S. Quality-of-life assessment in clinical trials. Cancer Treat Res. 1995;75:225-246.
30. Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: A retrospective analysis based on individual patient data from six consecutive studies. Cancer. 2005;104:1742-1750.
31. Gennari A, Amadori D, De Lena M, et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol. 2006;24:3912-3918.
32. Ghersi D, Wilcken N, Simes RJ. A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer. 2005;93:293-301.
33. Hackshaw A, Knight A, Barrett-Lee P, Leonard R. Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. Br J Cancer. 2005;93:1215-1221.
34. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. J Clin Oncol. 2001;19:1707-1715.
35. Jassem J, Pluzanska A, Pienkowski T, et al. Randomized phase III multicenter trial of doxorubicin and paclitaxel (AT) versus fluorouracil- doxorubicin-cyclophosphamide (FAC) as first-line therapy metastatic breast cancer (MBC): Long-term efficacy and external review of results. San Antonio Breast Cancer Symposium. San Antonio, Texas, USA, 2004. Abstract 5043.
36. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer [see comment]. J Clin Oncol. 2005;23:5542-5551.
37. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
38. Langley RE, Carmichael J, Jones AL, et al. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol. 2005;23:8322-8330.
39. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-2676.
40. Moher D, Schulz KF, Altman D. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285:1987-1991.
41. Molenberghs G, Burzykowski T, Alonso A, Buyse M. A perspective on surrogate endpoints in controlled clinical trials. Stat Methods Med Res. 2004;13:177-206.
42. Molenberghs G, Buyse ME, Burzykowski T. The history of surrogate endpoint validation. In: Molenberghs G, Buyse ME, Burzykowski T, eds. Statistics for biology and health: The evaluation of surrogate endpoints. New York: Springer; 2005:67-82.
43. Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer [see comment]. J Clin Oncol. 1996;14:1858-1867.
44. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 1999;17:1413-1424.
45. Namer M, Soler-Michel P, Turpin F, et al. Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer. Eur J Cancer. 2001;37:1132-1140.
46. Niimi M, Yamamoto S, Fukuda H, et al. The Influence of handling censored data on estimating progression-free survival in cancer clinical trials (JCOG9913-A). Jpn J Clin Oncol. 2002;32:19-26.
47. Panageas KS, Ben-Porat L, Dickler MN, et al. When you look matters: The effect of assessment schedule on progression-free survival. J Natl Cancer Inst. 2007;99:428-432.
48. Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol. 2000;18:724-733.
49. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815-2834.
50. Parnes HL, Cirrincione C, Aisner J, et al. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. J Clin Oncol. 2003;21:1819-1824.
51. Perry MC, Kardinal CG, Korzun AH, et al. Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081. J Clin Oncol. 1987;5:1534-1545.
52. Pierga JY, Jouve M, Asselain B, et al. Randomized trial comparing two different modalities of administration of the same cytotoxic drugs in metastatic breast cancer. J Infus Chemother. 1995;5:197-200.
53. Pierga JY, Jouve M, Asselain B, et al. Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90). Br J Cancer. 1998;77:1474-1479.
54. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23:8664-8670.
55. Sargent DJ, Patiyil S, Yothers G, et al. End points for colon cancer adjuvant trials: Observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol. 2007;25:4569-4574.
56. Sargent DJ, Hayes DF. Assessing the measure of a new drug: Is survival the only thing that matters? J Clin Oncol. 2008;26:1922-1923.
57. Sjostrom J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer. 1999;35:1194-1201.
58. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer:An intergroup trial (E1193). J Clin Oncol. 2003;21:588-592.
59. SledgeGW Jr, Hu P, Falkson G, et al. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol. 2000;18:262-266.
60. Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol. 1999;17:3403-3411.
61. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol. 1992;10:117-127.
62. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol. 2007;25:4562-4568.
63. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-181.
64. V. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) & Center for Biologics Evaluation and Research (CBER). Oncologic Drugs Advisory Committee Meeting December 16, 2003.
65. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) & Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Clinical trial endpoints for the approval of cancer drugs and biologics. [Draft Guidance]. 2005:1-26.
66. Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and leukemia group B trial 9342. J Clin Oncol. 2004;22:2061-2068.
67. Yu RX, Holmgren E. Endpoints for agents that slow tumor growth. Contemp Clin Trials. 2007;28:18-24.
68. Zielinski C, Beslija S, Mrsic-Krmpotic Z, et al. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: A Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. J Clin Oncol. 2005;23:1401-1408.